The EEG during Sleep is a Window to the Mind: Recurrence Analysis of the Sleep EEG Accurately Identifies Subjects with Mental Health Symptoms

David E. McCarty¹, Naresh M. Punjabi², Paul Y. Kim¹, Clifton Frilot II³, Andrew A. Marino¹

¹Division of Sleep Medicine, Department of Neurology, LSU Health, Shreveport, LA;
²Department of Pulmonary & Critical Care Medicine, Johns Hopkins Medicine,
Baltimore, MD;
³School of Allied Health Professions, LSU Health, Shreveport, LA

Abstract

Analysis of brain recurrence (ABR) is a novel method of algorithmically quantifying the degree of non-randomness (complexity) in an EEG signal. We showed that ABR accurately identified a signature in the sleep EEG that was specific for the presence of mental health symptoms, as assessed using the MHI-5 questionnaire.

Introduction

Our objective was to discover and validate reliable biomarkers in the EEG for detecting the presence and severity of mental illness. We used ABR (described in earlier publications) to extract four biomarkers from each 30-second epoch of sleep-staged EEGs. A reliable biomarker function for classifying the subjects according to MHI-5 scores was identified using linear discriminant analysis.
**Methods**

The study sample comprised subjects drawn from the SHHS for whom mental health symptomatology had been ascertainment, based on the Mental Health Index (MHI-5). MHI-5 scores were scaled to disperse values between 0 and 100, higher values indicating better mental health. From eligible subjects, we selected 34 subjects with MHI-5 scores >50, and 34 subjects matched for sex, BMI, age, and race with MHI-5 scores <50. Sleep-stage-specific ABR biomarkers were computed from the EEG (C3), and analyzed using LDA to identify combinations of the biomarkers that reliably classified individual subjects into low versus high MHI-5 scores. The classification accuracy was assessed using AUROC, with 10-fold cross-validation analysis.

### Characteristics of the study cohort

<table>
<thead>
<tr>
<th></th>
<th>LOW MHI-5 (&lt;50)</th>
<th>High MHI-5 (&gt;50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>34</td>
<td>34</td>
</tr>
<tr>
<td>Race (C/non-C)</td>
<td>29/5</td>
<td>29/5</td>
</tr>
<tr>
<td>Age (Y)</td>
<td>58.6 ± 2.3</td>
<td>58.7 ± 2.3</td>
</tr>
<tr>
<td>Male/Female</td>
<td>12/22</td>
<td>12/22</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.6 ± 0.6</td>
<td>25.9 ± 0.6</td>
</tr>
<tr>
<td>RDI</td>
<td>1.6 ± 0.2</td>
<td>1.3 ± 0.2</td>
</tr>
<tr>
<td>MHI-5</td>
<td>40.5 ± 1.4</td>
<td>78.4 ± 2.1</td>
</tr>
</tbody>
</table>

Mean ± SE. C, Caucasian RDI: Respiratory disturbance index

### Distribution of MHI-5 scores in subjects in each sub-cohort

![Graph showing distribution of MHI-5 scores in subjects in each sub-cohort]
Analysis of Brain Recurrence (ABR)

Complexity model

- Connectivity model furnishes basis for EEG biomarkers

Feature extraction

- R markers and D markers that characterize the pattern

Biomarkers constructed from the pattern and from the way it changes

\[ R, \Delta R, D, \Delta D \]
Experimental Design

Study Cohort
N = 34 (MHI5 < 50)
N = 34 (MHI5 > 50)

 Overnight EEG (C3)

Analysis of Brain Recurrence

ΔR(t)  R(t)  D(t)  ΔD(t)

Fragmentation Biomarkers
WASO, N1/N2, N3, REM

Depth Biomarkers
WASO, N1/N2, N3, REM

Depth Biomarkers
WASO, N1/N2, N3, REM

Depth Biomarkers
WASO, N1/N2, N3, REM

Linear Discriminant Analysis
(16 markers)

AUROC Analysis
for classification into
Low MHI5 (<50)
or
High MHI5 (>50)
Sub-Cohorts

The depth (R(t), D(t)) and fragmentation (ΔR(t), ΔD(t)) time series were normalized by WASO yielding 16 sleep-stage-specific biomarkers (WASO and 3 normalized stage-specific biomarkers for each time series (line 5)) that were used to create a biomarker function for discriminating between MHI-5 < 50 and MHI-5 > 50.
Results

Typical result for time-dependent change in the R depth biomarker

Values of R were calculated second-by-second, averaged epoch-by-epoch, and color-coded by sleep stage. Insert shows the sleep-stage-specific mean values. Distribution of generalized arousals computed from ΔR shown in lower curve. Each arousal (color-coded by sleep stage) indicated the occurrence of abrupt changes in R. Locations of arousals were jittered to facilitate graphical recognition. $P_r$, *a posteriori* stage-specific probability of an arousal (number of arousals in a given stage divided by the maximum possible number).
Average results showing biomarker differences between sub-cohorts

Relation between MHI-5 scores and sleep-stage-specific changes in percent recurrence (R) and percent determinism (D), and sleep-stage-specific changes in variances (generalized arousal indices) computed from $\Delta R$ and $\Delta D$. Stage-specific results were determined, normalized by the WASO values, and averaged across 34 subjects with higher (>50) and 34 with lower (<50) MHI-5 scores (mean ± SE). A trend of average differences occurred across the individual biomarkers, but no single biomarker differed between the groups at $P < 0.05$. 
Biomarker value versus MHI-5 for full cohort and restricted cohort

**Full Cohort**
- N = 68
- r = 0.36
- Sensitivity 79%
- Specificity 77%
- AUROC = 82%
- Cross-validation = 72%

**Restricted Cohort**
- N = 40
- r = 0.54
- Sensitivity 85%
- Specificity 85%
- AUROC = 89%
- Cross-validation = 82%

Dotted line indicates thresholds for classification into higher or lower groups, 0.44 and 0.53 for the full and restricted (subjects with the 20 highest and 20 lowest MHI-5) cohorts, respectively. When the small differences in the individual biomarkers between the groups were combined using LDA, the resulting biomarker function accurately classified the subjects (AUROC 82%, 89%), and the biomarker values correlated with disorder severity (r = 0.36, 0.54).
Discussion

ABR is a nonlinear method of algorithmically quantifying the degree of non-randomness (complexity) within a moving timeframe in an EEG signal. When applied to the staged, sleep-acquired EEG, the method yielded delocalized variables that tracked traditional stage-related concepts of sleep depth and fragmentation. We postulated that ABR-derived biomarkers could be combined statistically to accurately identify a signature specific for the presence of mental health symptoms. The assumption was tested by determining whether subjects could be reliably classified according to symptom severity as assessed using MHI-5 scores.

Using 12 ABR biomarkers, we classified 68 subjects into either low- or high-MHI-5 scores, with an AUROC of 82%. We interpret this result to mean that symptoms of psychological distress could be objectively detected in the EEG. Moreover, when subjects with mid-range MHI-5 scores were removed, subjects with intact mental health could be differentiated from those with more severe affective symptoms with even more precision (AUROC of 89%).

Diagnostic and prognostic information about numerous pathologies known to negatively affect neurobehavioral function—such as mental illness, traumatic brain injury, and chronic partial sleep deprivation—may be hiding in plain sight. More research regarding the clinical applicability of ABR is urgently needed.
References


Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABR</td>
<td>Analysis of brain recurrence</td>
</tr>
<tr>
<td>AUROC</td>
<td>Area under the receiver operating characteristics curve</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>EEG</td>
<td>Electroencephalogram</td>
</tr>
<tr>
<td>LDA</td>
<td>Linear discriminant analysis</td>
</tr>
<tr>
<td>MHI-5</td>
<td>Mental Health Index-5</td>
</tr>
<tr>
<td>RDI</td>
<td>Respiratory disturbance index</td>
</tr>
<tr>
<td>SHHS</td>
<td>Sleep Heart Health Study</td>
</tr>
</tbody>
</table>